Panobinostat
Malignant Rhabdoid Tumor
Australian & New Zealand Children's Haematology/Oncology GroupSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Malignant Rhabdoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Care T Cells Baylor College of Medicine | Phase 1 | CC |
Sc-Car.Gpc3Xil15.21 Car T Cells Seattle Children's Hospital | Phase 1 | CC |
Catch T Cells Baylor College of Medicine | Phase 1 | CC |
21.15.gpc3-car t cells Baylor College of Medicine | Phase 1 | CC |
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →